Literature DB >> 31157275

Surrogate endpoints in immunotherapy trials for solid tumors.

Fausto Petrelli1, Michele Ghidini2, Antonio Costanzo3, Valentina Rampulla3, Antonio Varricchio3, Gianluca Tomasello2.   

Abstract

Entities:  

Year:  2019        PMID： 31157275      PMCID： PMC6511564          DOI： 10.21037/atm.2019.03.20

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  14 in total

1.  Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors.

Authors:  Tai-Tsang Chen
Journal:  J Natl Cancer Inst       Date:  2015-06-25       Impact factor: 13.506

2.  Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study.

Authors:  Shunsuke Teraoka; Daichi Fujimoto; Takeshi Morimoto; Hayato Kawachi; Munehiro Ito; Yuki Sato; Kazuma Nagata; Atsushi Nakagawa; Kojiro Otsuka; Keiichiro Uehara; Yukihiro Imai; Kaori Ishida; Junya Fukuoka; Keisuke Tomii
Journal:  J Thorac Oncol       Date:  2017-09-20       Impact factor: 15.609

3.  End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Authors:  Daniel J Sargent; Smitha Patiyil; Greg Yothers; Daniel G Haller; Richard Gray; Jacqueline Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; David Kerr; Erin Green; Harry S Wieand; Richard M Goldberg; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2007-09-17       Impact factor: 44.544

4.  Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.

Authors:  Xavier Paoletti; Koji Oba; Yung-Jue Bang; Harry Bleiberg; Narikazu Boku; Olivier Bouché; Paul Catalano; Nozomu Fuse; Stefan Michiels; Markus Moehler; Satoshi Morita; Yasuo Ohashi; Atsushi Ohtsu; Arnaud Roth; Philippe Rougier; Junichi Sakamoto; Daniel Sargent; Mitsuru Sasako; Kohei Shitara; Peter Thuss-Patience; Eric Van Cutsem; Tomasz Burzykowski; Marc Buyse
Journal:  J Natl Cancer Inst       Date:  2013-10-09       Impact factor: 13.506

5.  Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center.

Authors:  Aaron Lisberg; D Andrew Tucker; Jonathan W Goldman; Brian Wolf; James Carroll; Ariana Hardy; Karolyn Morris; Paulina Linares; Carlos Adame; Marshall L Spiegel; Courtney Wells; Jordan McKenzie; Blanca Ledezma; Melody Mendenhall; Phillip Abarca; Krikor Bornazyan; Jaime Hunt; Nima Moghadam; Natalie Chong; Danielle Nameth; Caitlin Marx; John Madrigal; Sitaram Vangala; Narek Shaverdian; David Elashoff; Edward B Garon
Journal:  Cancer Immunol Res       Date:  2018-01-30       Impact factor: 11.151

Review 6.  Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies.

Authors:  Giandomenico Roviello; Fabrice Andre; Sergio Venturini; Barbara Pistilli; Giuseppe Curigliano; Massimo Cristofanilli; Pietro Rosellini; Daniele Generali
Journal:  Eur J Cancer       Date:  2017-10-19       Impact factor: 9.162

7.  Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.

Authors:  Stefan Michiels; Aurélie Le Maître; Marc Buyse; Tomasz Burzykowski; Emilie Maillard; Jan Bogaerts; Jan B Vermorken; Wilfried Budach; Thomas F Pajak; Kian K Ang; Jean Bourhis; Jean-Pierre Pignon
Journal:  Lancet Oncol       Date:  2009-02-24       Impact factor: 41.316

8.  Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.

Authors:  Georgia Ritchie; Harry Gasper; Johnathan Man; Sally Lord; Ian Marschner; Michael Friedlander; Chee Khoon Lee
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

Review 9.  Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials.

Authors:  Fausto Petrelli; Andrea Coinu; Mary Cabiddu; Karen Borgonovo; Mara Ghilardi; Veronica Lonati; Sandro Barni
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

10.  Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.

Authors:  Koji Haratani; Hidetoshi Hayashi; Yasutaka Chiba; Keita Kudo; Kimio Yonesaka; Ryoji Kato; Hiroyasu Kaneda; Yoshikazu Hasegawa; Kaoru Tanaka; Masayuki Takeda; Kazuhiko Nakagawa
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777
View more
  1 in total

1.  Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis.

Authors:  Peey-Sei Kok; Won-Hee Yoon; Sally Lord; Ian Marschner; Michael Friedlander; Chee Khoon Lee
Journal:  JCO Precis Oncol       Date:  2021-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.